Preparation and characterization of biodegradable or enteric-coated microspheres containing the protease inhibitor camostat.
We have produced biodegradable or enteric-coated microspheres containing camostat mesylate, a protease inhibitor, using a water-oil-water emulsion solvent evaporation method. The characteristics of the microspheres were determined. When polylactic acid, a biodegradable polymer, was used as a wall material, the optimized microsphere obtained showed a loading efficiency of almost 95% and had a mean diameter of 30 microm. This microsphere showed a sustained-release profile, with nearly 25% of drug being released at seven days in a dissolution test. When hypromellose acetate succinate (AS-HG type, with a high content of succinyl group) was used as an enteric wall material, optimized microspheres showed a loading efficiency of almost 80%. In this case, pH 3.0 citrate buffer was used as an internal aqueous phase, and citrate buffer containing 0.5% polyvinylalcohol was used as the external aqueous phase. These microspheres showed a rapid release profile in pH 6.8 buffer, whereas the release was extremely slow in pH 1.2 buffer. Hypromellose acetate succinate microspheres were also prepared containing 10% (w/w) N-benzoyl-dl-arg-4-nitroanilide as a model substrate for trypsin, with or without 5% (w/w) camostat. These microspheres were incubated in pH 6 or 7 buffer containing trypsin at 37 degrees C. When camostat was included in the microspheres, the substrate was protected from attack by trypsin, while in the absence of camostat, the released substrate was immediately attacked by trypsin to produce the degradation product N-benzoyl-dl-arginine.
Uchida
T
T
Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya City, Japan. takahiro@mwu.mukogawa-u.ac.jp
Yasuda
N
N
Matsuyama
K
K
D002021:Buffers; D002851:Chromatography, High Pressure Liquid; D004339:Drug Compounding; D004952:Esters; D005079:Excipients; D016670:Gabexate / Q000031:analogs & derivatives*; D006146:Guanidines / Q000008:administration & dosage*; D006863:Hydrogen-Ion Concentration; D019344:Lactic Acid / Q000737:chemistry; D008863:Microspheres; D011091:Polyesters; D011108:Polymers / Q000737:chemistry; D011480:Protease Inhibitors / Q000008:administration & dosage*; D013608:Tablets, Enteric-Coated
D002021:Buffers; D004952:Esters; D005079:Excipients; D006146:Guanidines; D011091:Polyesters; D011108:Polymers; D011480:Protease Inhibitors; D013608:Tablets, Enteric-Coated; C034532:camostat; D019344:Lactic Acid; C033616:poly(lactide); D016670:Gabexate